0.02
0.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Preveceutical Medical
Its shares trade on Canadian Securities Exchange under the ticker PREV.CN. It has been listed since 30 December 2016. In the fiscal year to 31 December 2019, it reported revenue of C$3,000 and a net loss of C$3.6m. At that date it held total assets of C$857,600 and shareholders' equity of −C$4.5m.
PreveCeutical Medical, Inc. engages in licensing, branding, and marketing of nutraceutical and wellness products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-12-30. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its Non-Addictive Analgesic is an engineering non-addictive analgesic peptide for pain management. Its Dual Gene Therapy targets type 2 diabetes and obesity. The Company’s subsidiary, PreveCeutical (Australia) Pty Ltd., manages its research programs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 30 Dec 2016
- Website
- preveceutical.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Preveceutical Medical Inc develops innovative cannabinoid-based therapies in Vancouver, Canada.
- PreveCeutical (Australia) Pty Ltd. manages research programs for the company's pipeline.
- The company's pipeline includes Cannabinoid Sol-Gel and Non-Addictive Analgesic for pain management.
Weaknesses
- The company's IPO was on 30 December 2016, a relatively recent listing.
- PreveCeutical Medical Inc focuses on nutraceutical and wellness products without specific market share data.
- The company's pipeline includes multiple programs without clear commercialization timelines.
Opportunities
- The Cannabinoid Sol-Gel targets neurological disorders and pain management in the growing wellness market.
- The Non-Addictive Analgesic addresses the opioid crisis with a non-addictive solution.
- The BSV Peptide Program targets cancer progression, a significant healthcare opportunity.
Threats
- The Dual Gene Therapy for type 2 diabetes and obesity faces competition from established pharmaceuticals.
- The company's reliance on a single subsidiary in Australia for research management may pose operational risks.
- Regulatory challenges in the nutraceutical and wellness sectors could impact product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.